Bio-marker schreef op 22 december 2017 11:39:
Thanks!
Samenvatting wat te verwachten ziet er veelbelovend uit:
Capla
• H1’18: Potential BLA filing in the U.S.A.
• H2’18: Possible Marketing Authorisation in Europe
• H2’18: Potential first commercial sales of caplacizumab in Germany
ALX-0171
• H1’18: Plan to initiate clinical study in Japanese infants
• H1’18: Plan to initiate clinical study in HSC transplant patients infected with RSV
• H2’18: RESPIRE Phase IIb topline results in RSV infected infants expected
VOBA
• H1’18: STEADY Phase II SLE topline results expected
• 2018: AbbVie opt-in decision on SLE and RA
• 2018: If AbbVie doesn’t opt in, explore new partnership opportunities
Other programmes
• 2018: expect multiple Phase I, II and III trials to be initiated in our partnered programmes
• 2018: anticipate readouts for several partnered clinical stage assets
• 2018: possible expansion of existing partnerships or addition of new partners